Abstract: Embodiments of the invention relate to a method, system, and computer program product for validating a data structure, comprising: responsive to identifying a data structure in a first programming language, identifying an equivalent data structure in a second programming language; comparing a data definition of the data structure with a data definition of the equivalent data structure; determining an incompatibility between a compared data definition of the data structure and a compared data definition of the equivalent data structure; and responsive to determining an incompatibility, identifying a rule defining an action to be taken in order to correct the incompatibility.

Abstract: Avoiding failure repetition in data processing includes storing a sequence of circumstances leading up to a previous failure, monitoring circumstances in a current process, matching a sequence of circumstances in the current process to a stored sequence of circumstances, and applying rules to determine if the current process should proceed.

Abstract: Embodiments of the invention relate to a method, system, and computer program product for validating a data structure, comprising: responsive to identifying a data structure in a first programming language, identifying an equivalent data structure in a second programming language; comparing a data definition of the data structure with a data definition of the equivalent data structure; determining an incompatibility between a compared data definition of the data structure and a compared data definition of the equivalent data structure; and responsive to determining an incompatibility, identifying a rule defining an action to be taken in order to correct the incompatibility.

Abstract: Embodiments of the invention relate to a method, system, and computer program product for validating a data structure, comprising: responsive to identifying a data structure in a first programming language, identifying an equivalent data structure in a second programming language; comparing a data definition of the data structure with a data definition of the equivalent data structure; determining an incompatibility between a compared data definition of the data structure and a compared data definition of the equivalent data structure; and responsive to determining an incompatibility, identifying a rule defining an action to be taken in order to correct the incompatibility.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Abstract: The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain pyruvamide compounds of the following formula (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Abstract: The present invention pertains generally to the field of therapeutic compounds and more specifically to certain pyruvamide compounds of the formula (X) (for convenience, collectively referred to herein as “PVA compounds”), which, inter alia, inhibit a dust mite Group 1 peptidase allergen (e.g., Der p 1, Der f 1, Eur m 1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit a dust mite Group 1 peptidase allergen, and in the treatment of diseases and disorders that are mediated by a dust mite Group 1 peptidase allergen; that are ameliorated by the inhibition of a dust mite Group 1 peptidase allergen; asthma; rhinitis; allergic conjunctivitis; atopic dermatitis; an allergic condition which is triggered by dust mites; an allergic condition which is triggered by a dust mite Group 1 peptidase allergen; and canine atopy.

Abstract: Embodiments of the invention relate to a method, system, and computer program product for validating a data structure, comprising: responsive to identifying a data structure in a first programming language, identifying an equivalent data structure in a second programming language; comparing a data definition of the data structure with a data definition of the equivalent data structure; determining an incompatibility between a compared data definition of the data structure and a compared data definition of the equivalent data structure; and responsive to determining an incompatibility, identifying a rule defining an action to be taken in order to correct the incompatibility.

Abstract: Avoiding failure repetition in data processing includes storing a sequence of circumstances leading up to a previous failure, monitoring circumstances in a current process, matching a sequence of circumstances in the current process to a stored sequence of circumstances, and applying rules to determine if the current process should proceed.

Abstract: The present invention relates to the use of an inhibitor of cysteine proteinase activity in conjunction with an inhibitor of any serine proteinase activity other than trypsin for the manufacture of a medicament for the prevention or treatment of a condition in which an allergen traverses an epithelial barrier such as asthma. Also included in the invention are formulations and kits containing serine and cysteine proteinase inhibitors and their use in the prevention or treatment of conditions in which an allergen traverses an epithelial barrier.